INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 8 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,549 | -0.5% | 9,295,000 | -21.2% | 3.76% | -4.1% |
| Q2 2023 | $12,609 | -5.2% | 11,795,000 | 0.0% | 3.92% | -6.2% |
| Q1 2023 | $13,303 | +10.6% | 11,795,000 | 0.0% | 4.18% | +16.5% |
| Q4 2022 | $12,029 | -99.9% | 11,795,000 | 0.0% | 3.59% | -7.8% |
| Q3 2022 | $12,434,000 | +23.3% | 11,795,000 | 0.0% | 3.89% | +39.5% |
| Q2 2022 | $10,081,000 | +85.9% | 11,795,000 | +81.5% | 2.79% | +119.4% |
| Q2 2021 | $5,424,000 | +0.1% | 6,500,000 | 0.0% | 1.27% | -3.5% |
| Q1 2021 | $5,420,000 | +41.2% | 6,500,000 | +30.0% | 1.32% | +34.8% |
| Q4 2020 | $3,839,000 | -18.6% | 5,000,000 | 0.0% | 0.98% | -25.6% |
| Q3 2020 | $4,719,000 | – | 5,000,000 | – | 1.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |